Evidence map›Paper›PMID 26913291›Full record

ArticleNeurology(R) neuroimmunology & neuroinflammation2016

The VZV/IE63-specific T cell response prevents herpes zoster in fingolimod-treated patients.

Amandine Mathias, Guillaume Perriard, Mathieu Canales, Fanny Vuilleumier, Gaetano Perrotta, Myriam Schluep, Renaud Du Pasquier

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology(R) neuroimmunology & neuroinflammation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Ocrelizumab Impairs the Phenotype and Function of Memory CD8Neurology(R) neuroimmunology & neuroinflammation · 2023
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Amandine MathiasLaboratory of Neuroimmunology, Center of Research in Neurosciences (A.M., G. Perriard, M.C., F.V., R.D.P.), and Service of Neurology (G. Perrotta, M.S., R.D.P.), Department of Clinical Neurosciences, CHUV, Lausanne, Switzerland.
Guillaume PerriardLaboratory of Neuroimmunology, Center of Research in Neurosciences (A.M., G. Perriard, M.C., F.V., R.D.P.), and Service of Neurology (G. Perrotta, M.S., R.D.P.), Department of Clinical Neurosciences, CHUV, Lausanne, Switzerland.
Mathieu CanalesLaboratory of Neuroimmunology, Center of Research in Neurosciences (A.M., G. Perriard, M.C., F.V., R.D.P.), and Service of Neurology (G. Perrotta, M.S., R.D.P.), Department of Clinical Neurosciences, CHUV, Lausanne, Switzerland.
Fanny VuilleumierLaboratory of Neuroimmunology, Center of Research in Neurosciences (A.M., G. Perriard, M.C., F.V., R.D.P.), and Service of Neurology (G. Perrotta, M.S., R.D.P.), Department of Clinical Neurosciences, CHUV, Lausanne, Switzerland.
Gaetano PerrottaLaboratory of Neuroimmunology, Center of Research in Neurosciences (A.M., G. Perriard, M.C., F.V., R.D.P.), and Service of Neurology (G. Perrotta, M.S., R.D.P.), Department of Clinical Neurosciences, CHUV, Lausanne, Switzerland.
Myriam SchluepLaboratory of Neuroimmunology, Center of Research in Neurosciences (A.M., G. Perriard, M.C., F.V., R.D.P.), and Service of Neurology (G. Perrotta, M.S., R.D.P.), Department of Clinical Neurosciences, CHUV, Lausanne, Switzerland.
Renaud Du PasquierLaboratory of Neuroimmunology, Center of Research in Neurosciences (A.M., G. Perriard, M.C., F.V., R.D.P.), and Service of Neurology (G. Perrotta, M.S., R.D.P.), Department of Clinical Neurosciences, CHUV, Lausanne, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess longitudinally the antiviral immune response of T cells from patients with multiple sclerosis (MS) treated with fingolimod (FTY) vs other disease-modifying treatments (DMTs).

methodsWe assessed cellular immune responses specific to influenza virus (FLU), JC virus (JCV), and varicella-zoster virus (VZV) using quantification of interferon-γ secretion by enzyme-linked immunospot in patients with MS on FTY (n = 31), including 2 with herpes zoster (HZ), natalizumab (n = 11), and other DMTs (n = 11). We used viral lysates for FLU and VZV and a pool of peptides for FLU, JCV (VP-1), and VZV (IE63).

resultsBesides an expected drop of T cells, we found that, proportionally to the number of CD3(+) T cells, only FTY-treated patients with MS exhibited an increased VZV/IE63-specific T cell response peaking 6 months into treatment, a response that returned to baseline after 12 and 24 months. Two FTY-treated patients developed an HZ 6 months into treatment, coinciding with an absent VZV/IE63-specific T cell response. However, cellular immune responses specific to VZV lysate, JCV, and FLU (lysate and pool of peptide epitopes) were similar between all 3 categories (FTY, natalizumab, and other DMTs) of study patients.

conclusionsFTY-treated patients with MS exhibit an increased VZV/IE63-specific cellular immune response after 6 months of treatment. FTY-treated patients who develop an HZ are not able to mount such a response, suggesting that a T cell response directed against this viral protein may be key in preventing the occurrence of HZ.

Identifiers

PMID26913291
PMCPMC4751153

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.